{"filing":{"accession_number":"0001628280-26-048469","cik":"0001787306","ticker":"ARQT","company_name":"Arcutis Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"arqt-20260715.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026048469/arqt-20260715.htm"},"events":[{"id":18437,"run_id":16574,"accession_number":"0001628280-26-048469","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Christopher Peetz was appointed as a new member of the Board of Directors effective July 15, 2026, with the Board increasing authorized directors from nine to ten. Peetz brings extensive biopharmaceutical leadership experience, including his current CEO role at Mirum Pharmaceuticals, and received an initial stock option award of 21,486 shares plus prorated annual equity and cash retainer.","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17243,"accession_number":"0001628280-26-048469","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Christopher Peetz as a new member of the Board of Directors effective July 15, 2026, with the Board increasing authorized directors from nine to ten. The principal action is Peetz taking a director role, making this an executive appointment. The disclosure includes his qualifications, independence determination, and compensation arrangement (initial stock option award of 21,486 shares plus prorated annual equity and cash retainer), which is material to investors assessing board composition and governance at a commercial-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:26:54.956610+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17244,"accession_number":"0001628280-26-048469","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Christopher \"Chris\" Peetz to the Arcutis Board of Directors effective July 15, 2026. The press release emphasizes his extensive biopharmaceutical leadership experience, including current CEO role at Mirum Pharmaceuticals and prior executive positions at multiple companies. Board appointments of experienced executives are material governance events affecting investor assessment of company leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:26:54.956610+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17243,"accession_number":"0001628280-26-048469","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Christopher Peetz as a new member of the Board of Directors effective July 15, 2026, with the Board increasing authorized directors from nine to ten. The principal action is Peetz taking a director role, making this an executive appointment. The disclosure includes his qualifications, independence determination, and compensation arrangement (initial stock option award of 21,486 shares plus prorated annual equity and cash retainer), which is material to investors assessing board composition and governance at a commercial-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:26:54.956610+00:00","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-07-16"},{"id":17244,"accession_number":"0001628280-26-048469","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Christopher \"Chris\" Peetz to the Arcutis Board of Directors effective July 15, 2026. The press release emphasizes his extensive biopharmaceutical leadership experience, including current CEO role at Mirum Pharmaceuticals and prior executive positions at multiple companies. Board appointments of experienced executives are material governance events affecting investor assessment of company leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:26:54.956610+00:00","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-07-16"}]}